LncRNA FOXD2‐AS1 accelerates the papillary thyroid cancer progression through regulating the miR‐485‐5p/KLK7 axis

2018 ◽  
Vol 120 (5) ◽  
pp. 7952-7961 ◽  
Author(s):  
Yayuan Zhang ◽  
Jintao Hu ◽  
Wenbing Zhou ◽  
Hengyuan Gao
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Progression ◽  
Papillary Thyroid

scholarly journals LncRNA LINC00460 promotes the papillary thyroid cancer progression by regulating the LINC00460/miR-485-5p/Raf1 axis

2019 ◽  
Vol 52 (1) ◽  
Author(s):  
Guangjun Li ◽  
Qingli Kong
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Progression ◽  
Binding Sites ◽  
Luciferase Reporter ◽  
Reporter Assay ◽  
Papillary Thyroid ◽  
Potential Biomarker ◽  
Common Malignancy

Abstract Background Papillary thyroid cancer (PTC) is the most common malignancy of all thyroid cancers. LncRNA LINC00460 has been proved to play roles in the oncogenesis and progression of various tumors, including papillary thyroid cancer. However, the potential molecular mechanism of LINC00460 in PTC is poorly investigated. Results LINC00460 was upregulated in PTC tissues and cells. Raf1 was upregulated in PTC tissues, but miR-485-5p was down-regulated. High LINC00460 expression was associated with poor prognosis. LINC00460 knockdown suppressed proliferation, migration, invation and EMT of PTC cells. Bioinformatics prediction revealed that LINC00460 had binding sites with miR-485-5p, which was validated by luciferase reporter assay. In addition, miR-485-5p was confirmed to directly target Raf1 3′-UTR. Moreover, LINC00460 promoted PTC progression by sponging miR-485-5p to elevate the expression of Raf1. Knockdown of LINC00460 restrained tumor growth in vivo. Conclusion LINC00460 induced proliferation, migration, invation and EMT of PTC cells by regulating the LINC00460/miR-485-5p/Raf1 axis, which indicated that LINC00460 may be a potential biomarker and therapeutic target for PTC.

scholarly journals Mouse Models of Follicular and Papillary Thyroid Cancer Progression

2012 ◽  
Vol 2 ◽  
Author(s):  
Marika A. Russo ◽  
Valeria G. Antico Arciuch ◽  
Antonio Di Cristofano
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Mouse Models ◽  
Cancer Progression ◽  
Papillary Thyroid

scholarly journals KCNN4 is a diagnostic and prognostic biomarker that promotes papillary thyroid cancer progression

Aging ◽  
2020 ◽  
Vol 12 (16) ◽  
pp. 16437-16456
Author(s):  
Jialiang Wen ◽  
Bangyi Lin ◽  
Lizhi Lin ◽  
Yizuo Chen ◽  
Ouchen Wang
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Progression ◽  
Prognostic Biomarker ◽  
Papillary Thyroid

scholarly journals Papillary Thyroid Cancer Prognosis: An Evolving Field

Cancers ◽  
2021 ◽  
Vol 13 (21) ◽  
pp. 5567
Author(s):  
Salvatore Ulisse ◽  
Enke Baldini ◽  
Augusto Lauro ◽  
Daniele Pironi ◽  
Domenico Tripodi ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Progression ◽  
Clinical Management ◽  
Cancer Prognosis ◽  
Driver Mutations ◽  
Clinical Approach ◽  
Papillary Thyroid ◽  
Cancer Driver ◽  
Staging Systems

Over the last few years, a great advance has been made in the comprehension of the molecular pathogenesis underlying thyroid cancer progression, particularly for the papillary thyroid cancer (PTC), which represents the most common thyroid malignancy. Putative cancer driver mutations have been identified in more than 98% of PTC, and a new PTC classification into molecular subtypes has been proposed in order to resolve clinical uncertainties still present in the clinical management of patients. Additionally, the prognostic stratification systems have been profoundly modified over the last decade, with a view to refine patients’ staging and being able to choose a clinical approach tailored on single patient’s needs. Here, we will briefly discuss the recent changes in the clinical management of thyroid nodules, and review the current staging systems of thyroid cancer patients by analyzing promising clinicopathological features (i.e., gender, thyroid auto-immunity, multifocality, PTC histological variants, and vascular invasion) as well as new molecular markers (i.e., BRAF/TERT promoter mutations, miRNAs, and components of the plasminogen activating system) potentially capable of ameliorating the prognosis of PTC patients.

scholarly journals The DLG1-AS1/miR-497/YAP1 axis regulates papillary thyroid cancer progression

Aging ◽  
2020 ◽  
Author(s):  
Yong Huang ◽  
KeWei Zhang ◽  
Yinghua Li ◽  
Yuyin Dai ◽  
Hongguang Zhao
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Progression ◽  
Papillary Thyroid

scholarly journals Immune landscape of papillary thyroid cancer and immunotherapeutic implications

2018 ◽  
Vol 25 (5) ◽  
pp. 523-531 ◽  
Author(s):  
Kwon Joong Na ◽  
Hongyoon Choi
Keyword(s):  
Thyroid Cancer ◽  
Papillary Thyroid Cancer ◽  
Cancer Progression ◽  
Negative Correlation ◽  
Immune Cell ◽  
Immune Escape ◽  
Critical Role ◽  
Significant Negative Correlation ◽  
The Cancer Genome Atlas ◽  
Papillary Thyroid

Although papillary thyroid cancer (PTC) is curable with excellent survival rate, patients with dedifferentiated PTC suffer the recurrence or death. As cancer immune escape plays a critical role in cancer progression, we aimed to investigate the relationship between differentiation and immune landscape of PTC and its implications for immunotherapy. Using The Cancer Genome Atlas data, we estimated the immune cell enrichment scores and overall immune infiltration, ImmuneScore, to characterize the immune landscape of PTC. Thyroid differentiation score (TDS) was calculated from 16 thyroid function genes. We demonstrated that ImmuneScore had a significant negative correlation with TDS, and BRAFV600E+ tumors showed significantly low TDS and high ImmuneScore. Enrichment scores of myeloid cells and B-cells were negatively correlated with TDS, while those of plasma cells were positively correlated with TDS. In addition, the association between TDS, ImmuneScore and immunosuppressive markers (CTLA-4, PD-L1, HLA-G) were evaluated according to BRAFV600E status. All immunosuppressive markers expression had a significant negative correlation with TDS, and they were significantly higher in BRAFV600E+ status. Subgroups were divided by median values of TDS and ImmuneScore, and immunosuppressive markers of these subgroups were compared. The immunosuppressive markers expression was the highest in high ImmuneScore and low TDS subgroup. Furthermore, ImmuneScore had a significant association with recurrence-free survival, irrespective of clinicopathologic factors including BRAFV600E status. These findings based on gene expression data illuminate the immune landscape of PTC and its association with TDS, immunosuppressive markers and recurrence. Our results would be extended to investigate immunotherapeutic approaches in PTC.

Sign in / Sign up

Export Citation Format

Share Document